期刊
EBIOMEDICINE
卷 72, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ebiom.2021.103625
关键词
Metastatic prostate cancer; Sphingosine kinase; Enzalutamide; Ceramide
资金
- National Health and Medical Research Council of Australia [GNT0614296, APP1196225, GNT1098647]
- Cancer Institute New South Wales [10/TPG/104, 2018/TPG001]
- Australian Prostate Cancer Research Centre-New South Wales
- Australian Department of Health and Aging
- Movember Foundation
- Prostate Cancer Foundation of Australia [MRTA3]
- Cancer Council New South Wales [PG 10-01]
- Cancer Council South Australia (Beat Cancer Project Principal Cancer Research Fellowship) [PRF1117]
- Victorian Government's Operational Infrastructure Support Program
- NHMRC Postgraduate Scholarship
- Monash University Postgraduate Publications Award
- Cancer Council Victoria Postdoctoral Fellowship
- Australian Government Research Training Program Scholarship
- Victorian Cancer Agency Clinical Research Fellowship [CRF14009]
- Astellas Investigator-Initiated Grant
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group's Noel Castan Fellowship
- Twin Towns Services Community Foundation
This study focused on investigating the association of ceramide-sphingosine-1-phosphate signalling axis with ARSI resistance in mCRPC. Elevated circulating ceramide levels were found to be associated with shorter radiological progression-free survival and overall survival in men with mCRPC. Combining AR aberrations with elevated ceramide levels resulted in a worse prognosis, and SPHK inhibitors showed potential to enhance the efficacy of enzalutamide.
Background: Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20-30% of men with metastatic castration-resistant prostate cancer (mCRPC). Ceramide metabolism may have a role in ARSI resistance. Our study's aim is to investigate the association of the ceramide-sphingosine-1-phosphate (ceramide-SIP) signalling axis with ARSI resistance in mCRPC. Methods: Lipidomic analysis (similar to 700 lipids) was performed on plasma collected from 132 men with mCRPC, before commencing enzalutamide or abiraterone. AR gene aberrations in 77 of these men were identified by deep sequencing of circulating tumour DNA. Associations between circulating lipids, radiological progression-free survival (rPFS) and overall survival (OS) were examined by Cox regression. Inhibition of ceramide S1P signalling with sphingosine kinase (SPHK) inhibitors (PF-543 and ABC294640) on enzalutamide efficacy was investigated with in vitro assays, and transcriptomic and lipidomic analyses of prostate cancer (PC) cell lines (LNCaP, C42B, 22Rv1). Findings: Men with elevated circulating ceramide levels had shorter rPFS (HR=2.3, 95% CI=1.5-3.6, p = 0.0004) and shorter OS (HR=2.3, 95% CI=1.4-36, p = 0.0005). The combined presence of an AR aberration with elevated ceramide levels conferred a worse prognosis than the presence of only one or none of these characteristics (median rPFS time = 3.9 vs 8.3 vs 17.7 months; median OS time = 8.9 vs 19.8 vs 34.4 months). SPHK inhibitors enhanced enzalutamide efficacy in PC cell lines. Transcriptomic and lipidomic analyses indicated that enzalutamide combined with SPHK inhibition enhanced PC cell death by SREBP-induced lipotoxicity. Interpretation: Ceramide-SIP signalling promotes ARSI resistance, which can be reversed with SPHK inhibitors. (C) 2021 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据